Hemochromatosis and Iron Overload: Diagnosis, Management and New Frontiers

Hemochromatosis and Iron Overload: Diagnosis, Management and New Frontiers

Comprehensive Lecture Summary

1. Main Clinical Topics Discussed

• Pathophysiology of iron homeostasis and its dysregulation in hereditary hemochromatosis (HH)
• Clinical recognition of hemochromatosis, including symptomatic and asymptomatic presentations
• Genetic basis of HH, including HFE mutations, penetrance, and family screening
• Multi-system manifestations of iron overload
• Diagnostic approach including iron studies, genetic testing, and liver biopsy
• Management principles including phlebotomy and environmental modifications
• Emerging molecules (hepcidin) in iron regulation

2. Key Learning Points, Guidelines, and Recommendations

Diagnosis

• Transferrin saturation (TS) is a key diagnostic marker:

- Calculated as: *Serum Iron ÷ TIBC × 100*

- UK diagnostic threshold: >45% (patient in case study had TS of 60%)

- Note: TS varies diurnally and with food intake; morning fasting measurement is preferred

• Ferritin thresholds of clinical significance:

- Men: >300 µg/L

- Pre-menopausal women: >200 µg/L

- Post-menopausal women: >300 µg/L

- Ferritin >1,000 µg/L warrants liver biopsy consideration, particularly when co-existing liver disease (e.g., NAFLD) is present

• Liver biopsy is indicated to assess degree of fibrosis/cirrhosis, especially with comorbid liver conditions

Genetic Testing

• Indicated in:

- Index patients with confirmed or suspected HH

- First-degree relatives of known HH cases

- Unexpected iron overload on liver biopsy

• Common HFE mutations:

- C282Y (cysteine → tyrosine at position 282) — most prevalent; homozygosity is classic HH

- H63D (histidine → aspartic acid at position 63)

- Compound heterozygote (C282Y/H63D) — clinically relevant

• Penetrance is incomplete: Carrying the HFE mutation does not guarantee clinical disease expression

Screening

• Siblings and first-degree relatives of confirmed HH patients must be screened
• Family pedigree construction is a valuable clinical tool

Management

• Phlebotomy (venesection): Standard treatment for symptomatic and confirmed HH
• Environmental/lifestyle modifications:

- Alcohol reduction

- Hepatitis A and B immunization

- Dietary counselling

3. Specific Clinical Data, Statistics, and Study Results Cited

• Case Study — "Sheamus," 60-year-old Irish male:

- Presenting symptoms: fatigue, joint pain, mild hepatomegaly (1 cm), tender MCP joints

- Alcohol: ~2 beers/day

- Liver tests: mildly elevated transaminases, normal bilirubin, normal fasting glucose

- Liver tests did not normalise after alcohol cessation — indicating a primary hepatic condition

- Iron studies: Ferritin 640 µg/L, Transferrin saturation 60%

- Genetic result: Homozygous C282Y — confirmed hereditary hemochromatosis

- Family history revealed: brother with T2DM (age 55), sister (age 64), father died of HCC secondary to hemochromatosis

• Iron Homeostasis:

- Approximately 50 mg of dietary iron is available daily from a balanced diet

- Iron regulation occurs primarily at the duodenal enterocyte level

- Iron excretion capacity is limited; control is fundamentally dependent on absorption regulation

- Key regulators: iron stores, erythroid activity, hypoxia, and inflammation

• Juvenile Hemochromatosis:

- Equal sex distribution

- Predominantly affects: cardiac, pituitary, pancreatic, and hepatic tissue

4.